Boston Scientific’s Pulse Races At Thought Of CRM Prospects

Confidence in the potential U.S. success of the Taxus paclitaxel-eluting stent is spurring Boston Scientific to charge forward with its long-term growth strategy of expanding the firm's core cardiology business